A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)

Key facts

Sponsor

Alnylam Pharmaceuticals

Principal Investigator

Nader Najafian, MD

Alnylam Pharmaceuticals

Intervention

Givosiran(drug)

Enrollment

10 enrolled

Eligibility

18-65 years · All sexes

Timeline

2018 – 2019

Study locations (1)

• Clinical Trial Site, Stockholm, Sweden

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute hepatic porphyria

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGNCT05344599
  Evaluating the Prevalence of Acute Hepatic Porphyria in Postural Tachycardia Syndrome
  Vanderbilt University Medical Center
• RECRUITINGNCT04883905
  ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
  Alnylam Pharmaceuticals

See all trials for Acute hepatic porphyria →